Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer

被引：0
|
作者：
José Miguel Jurado García
Alfonso Sánchez
Bella Pajares
Elisabeth Pérez
Lorenzo Alonso
Emilio Alba
机构：
[1] Hospital Universitario Virgen de la Victoria,Medical Oncology Service
来源：
Clinical and Translational Oncology | 2008年 / 10卷
关键词：
Ovarian cancer; Platinum resistant; Bevacizumab; Metronomic cyclophosphamide;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer
    José Miguel Jurado
    Alfonso Sánchez
    Bella Pajares
    Elisabeth Pérez
    Lorenzo Alonso
    Emilio Alba
    Clinical and Translational Oncology, 2008, 10 (11) : 772 - 772
  • [2] Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer
    Jurado Garcia, Jose Miguel
    Sanchez, Alfonso
    Pajares, Bella
    Perez, Elisabeth
    Alonso, Lorenzo
    Alba, Emilio
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2008, 10 (09): : 583 - 586
  • [3] Pembrolizumab in combination with bevacizumab and oral cyclophosphamide in heavily pre-treated platinum-resistant ovarian cancer
    Andrikopoulou, Angeliki
    Liontos, Michalis
    Skafida, Efthymia
    Koutsoukos, Konstantinos
    Apostolidou, Kleoniki
    Kaparelou, Maria
    Rouvalis, Angeliki
    Bletsa, Garyfallia
    Dimopoulos, Meletios-Athanasios
    Zagouri, Flora
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (04) : 571 - 576
  • [4] Bevacizumab toxicity in heavily pre-treated recurrent epithelial ovarian cancer
    Martin, I.
    Urban, R.
    Goff, B.
    GYNECOLOGIC ONCOLOGY, 2015, 139 (01) : 197 - 197
  • [5] Second complete remission induced by cyclophosphamide plus bevacizumab in two patients with heavily pre-treated ovarian cancer
    Sanchez-Munoz, Alfonso
    Miguel Jurado, Jose
    Perez-Ruiz, Elisabeth
    Alba, Emilio
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2009, 11 (05): : 329 - 331
  • [6] Second complete remission induced by cyclophosphamide plus bevacizumab in two patients with heavily pre-treated ovarian cancer
    Alfonso Sánchez-Muñoz
    José Miguel Jurado
    Elisabeth Pérez-Ruiz
    Emilio Alba
    Clinical and Translational Oncology, 2009, 11 : 329 - 331
  • [7] Bevacizumab in heavily pre-treated ovarian cancer patients and the predictive value of serum VEGF
    Smerdel, M.
    Steffensen, K. D.
    Waldstrom, M.
    Brandslund, I.
    Jakobsen, A.
    EJC SUPPLEMENTS, 2009, 7 (02): : 451 - 451
  • [8] Capecitabine and bevacizumab in heavily pre-treated patients with advanced colorectal cancer
    Larsen, Finn Ole
    Boisen, Mogens Karsbol
    Fromm, Annelene L.
    Jensen, Benny Vittrup
    ACTA ONCOLOGICA, 2012, 51 (02) : 231 - 233
  • [9] Bevacizumab plus microtubule targeting agents in heavily pre-treated ovarian cancer patients: a retrospective study
    Asmane, Irene
    Kurtz, Jean-Emmanuel
    Bajard, Agathe
    Guastalla, Jean-Paul
    Meeus, Pierre
    Tredan, Olivier
    Galy, Intidhar Labidi
    Moullet, Isabelle
    Ardisson, Philippe
    Vincent, Lionel
    Coeffic, David
    Dufresne, Armelle
    Bergerat, Jean-Pierre
    Ray-Coquard, Isabelle
    BULLETIN DU CANCER, 2011, 98 (09) : E80 - E89
  • [10] Oral etoposide in heavily pre-treated metastatic breast cancer: A retrospective series
    Giannone, G.
    Milani, A.
    Ghisoni, E.
    Genta, S.
    Mittica, G.
    Montemurro, F.
    Valabrega, G.
    BREAST, 2018, 38 : 160 - 164
12345